trending Market Intelligence /marketintelligence/en/news-insights/trending/dCrwQpo4WqfXqqV8brCFxQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Urovant bladder drug helps patients but falls short of beating another medicine

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Urovant bladder drug helps patients but falls short of beating another medicine

Urovant Sciences Ltd.'s stock dipped by over 18% following news that its medicine vibegron helped patients with overactive bladder but not significantly so when compared to a generic drug.

Urovant stocks were down 18.18% to $11.38 per share as of 1:23 p.m. on March 19, 2019.

The London-based biopharmaceutical company evaluated vibegron against placebo and another drug called tolterodine in a phase 3 trial dubbed Empowur, which included 1,518 patients with symptoms of overactive bladder.

After 12 weeks of treatment, patients receiving the 75-milligram dosage of vibegron showed statistical significance in reducing the daily instances of an urge to urinate — which is followed by an involuntary loss of urine — and a reduction in daily micturitions, or number of times a person urinates, when compared to placebo. Specifically, patients saw an improvement of 2 and 1.8 in incontinence and micturition, respectively, compared to 1.4 and 1.3 for placebo.

Patients who received tolterodine saw an improvement of 1.8 and 1.6 in incontinence and micturition, close to the improvements of vibegron.

The trial also met seven secondary goals, which included a statistically significant reduction in daily urgency episodes when compared to placebo.

Vibegron was well-tolerated during the study. Urovant plans to file for a U.S. approval of the drug by 2020, the company said in a March 19 press release.

Once approved, the drug would compete with Astellas Pharma Inc.'s overactive bladder therapy Myrbetriq. According to Fierce Pharma, Urovant believes its medicine is safer and provides quicker relief than Myrbetriq.